Marianne B. Treppendahl
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Journal: The New England journal of medicine
Published: April 08, 2024
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Journal: The New England journal of medicine
Published: August 25, 2023
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table.
Journal: European heart journal
Published: December 20, 2022
Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers.
Journal: Nature communications
Published: January 02, 2020
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Journal: Diabetes, obesity & metabolism
Published: September 30, 2019
Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
Journal: Diabetes, obesity & metabolism
Published: October 09, 2018
Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
Journal: Diabetes & vascular disease research
Published: June 28, 2018
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).
Journal: The American journal of cardiology
Published: December 13, 2017
Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes.
Journal: American journal of hematology
Published: September 02, 2016
Last Updated: 09/26/2026